Presently, over 40 players, based in different regions of the world claim to have the capability to manufacture ADC payloads / warheads, claims Roots Analysis

 Since 2000, several contract manufacturing organizations (CMOs) and contract development andmanufacturing organizations (CDMOs), offering HPAPI and cytotoxic drug related services have been established to cater to the rise in demand of cytotoxicpayloads in ADCs.

 








To order this 130+ page report, please visit

https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

 

The financial opportunity within the ADC cytotoxic payloads / warheads market has been analyzed across the following segments:

§  Type of Payload

 

§  Payload

 

§  Type of Product

  • Commercialized Products
  • Clinical Products

 

§  Key Geographical Regions 

  • North America
  • Europe
  • Asia Pacific

 

The “ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2030” report features the following companies, which we identified to be key players in this domain:

§  Abzena

§  Levana Biopharma

§  MabPlex

§  NJ Bio

§  Novasep

§  STA Pharmaceuticals

§  Synaffix

 

Table of Contents

 

1. Preface

 

2. Executive Summary

 

3. Introduction

 

4. MarketOverview

5. Company Profiles

 

6. Partnershipsand Collaborations

 

7. Recent Expansions

 

8. Funding and Investment Analysis

 

9. PatentAnalysis

 

10. Demand Analysis

 

11. Case Study: ADC Therapeutics

 

12. Case Study: ADC Contract Manufacturing Organizations

 

13. Market Forecast

 

14. Executive Insights

 

15. Appendix 1: List of Figures and Tables

 

16. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit

https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html

Contact:

Ben Johnson

+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

The patient recruitment and retention services market is estimated to be worth USD 5.3 billion in 2030

Image
A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers   Roots Analysis   is pleased to announce the publication of its recent study, titled, “ Patient Recruitment and Retention Services Marker, 2019-2030 . ”   The report offers a comprehensive study of the current scenario and future potential of the players providing patient enrollment and retention services. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape of companies offering patient recruitment and retention services. §   An analysis of the most active regions (in terms of patient recruitment activity) engaged in this domain, featuring schema...
Read more